Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

2.

Susceptibility of Clinical Isolates of Burkholderia pseudomallei to a Lipid A Biosynthesis Inhibitor.

Sengyee S, Saiprom N, Paksanont S, Limmathurotsakul D, Wuthiekanun V, Chantratita N.

Am J Trop Med Hyg. 2017 Jul;97(1):62-67. doi: 10.4269/ajtmh.16-0858.

3.

An avirulent Burkholderia pseudomallei ∆purM strain with atypical type B LPS: expansion of the toolkit for biosafe studies of melioidosis.

Norris MH, Rahman Khan MS, Schweizer HP, Tuanyok A.

BMC Microbiol. 2017 Jun 7;17(1):132. doi: 10.1186/s12866-017-1040-4.

4.

Within-Host Evolution of Burkholderia pseudomallei during Chronic Infection of Seven Australasian Cystic Fibrosis Patients.

Viberg LT, Sarovich DS, Kidd TJ, Geake JB, Bell SC, Currie BJ, Price EP.

MBio. 2017 Apr 11;8(2). pii: e00356-17. doi: 10.1128/mBio.00356-17.

5.

Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.

Bugrysheva JV, Sue D, Gee JE, Elrod MG, Hoffmaster AR, Randall LB, Chirakul S, Tuanyok A, Schweizer HP, Weigel LM.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00010-17. doi: 10.1128/AAC.00010-17. Print 2017 Jun.

6.

Loss of Methyltransferase Function and Increased Efflux Activity Leads to Doxycycline Resistance in Burkholderia pseudomallei.

Webb JR, Price EP, Currie BJ, Sarovich DS.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00268-17. doi: 10.1128/AAC.00268-17. Print 2017 Jun.

7.
8.

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response.

Cummings JE, Slayden RA.

PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005209. doi: 10.1371/journal.pntd.0005209. eCollection 2017 Jan.

9.

Secondary metabolites from Bacillus amyloliquefaciens isolated from soil can kill Burkholderia pseudomallei.

Boottanun P, Potisap C, Hurdle JG, Sermswan RW.

AMB Express. 2017 Dec;7(1):16. doi: 10.1186/s13568-016-0302-0. Epub 2017 Jan 4.

10.

Antibiotic resistance in Burkholderia species.

Rhodes KA, Schweizer HP.

Drug Resist Updat. 2016 Sep;28:82-90. doi: 10.1016/j.drup.2016.07.003. Epub 2016 Jul 30.

11.

Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis, Yersinia pestis, and Burkholderia pseudomallei by Use of Laser Light Scattering Technology.

Bugrysheva JV, Lascols C, Sue D, Weigel LM.

J Clin Microbiol. 2016 Jun;54(6):1462-71. doi: 10.1128/JCM.03251-15. Epub 2016 Mar 16.

12.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

13.

One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams.

King DT, Sobhanifar S, Strynadka NC.

Protein Sci. 2016 Apr;25(4):787-803. doi: 10.1002/pro.2889. Epub 2016 Mar 9. Review.

14.

Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei.

Randall LB, Dobos K, Papp-Wallace KM, Bonomo RA, Schweizer HP.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1509-14. doi: 10.1128/AAC.02444-15.

15.

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):777-88. doi: 10.1128/AAC.02073-15. Print 2016 Feb.

16.

A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Philippon A, Slama P, Dény P, Labia R.

Clin Microbiol Rev. 2016 Jan;29(1):29-57. doi: 10.1128/CMR.00019-15. Review.

17.

T Cell Immunity to the Alkyl Hydroperoxide Reductase of Burkholderia pseudomallei: A Correlate of Disease Outcome in Acute Melioidosis.

Reynolds C, Goudet A, Jenjaroen K, Sumonwiriya M, Rinchai D, Musson J, Overbeek S, Makinde J, Quigley K, Manji J, Spink N, Yos P, Wuthiekanun V, Bancroft G, Robinson J, Lertmemongkolchai G, Dunachie S, Maillere B, Holden M, Altmann D, Boyton R.

J Immunol. 2015 May 15;194(10):4814-24. doi: 10.4049/jimmunol.1402862. Epub 2015 Apr 10.

18.

Melioidosis: molecular aspects of pathogenesis.

Stone JK, DeShazer D, Brett PJ, Burtnick MN.

Expert Rev Anti Infect Ther. 2014 Dec;12(12):1487-99. doi: 10.1586/14787210.2014.970634. Epub 2014 Oct 14. Review.

19.

Burkholderia pseudomallei sequencing identifies genomic clades with distinct recombination, accessory, and epigenetic profiles.

Nandi T, Holden MT, Didelot X, Mehershahi K, Boddey JA, Beacham I, Peak I, Harting J, Baybayan P, Guo Y, Wang S, How LC, Sim B, Essex-Lopresti A, Sarkar-Tyson M, Nelson M, Smither S, Ong C, Aw LT, Hoon CH, Michell S, Studholme DJ, Titball R, Chen SL, Parkhill J, Tan P.

Genome Res. 2015 Jan;25(1):129-41. doi: 10.1101/gr.177543.114. Epub 2014 Sep 18. Erratum in: Genome Res. 2015 Apr;25(4):608. Holden, Mathew T G [corrected to Holden, Matthew T G].

20.

Rapid Burkholderia pseudomallei identification and antibiotic resistance determination by bacteriophage amplification and MALDI-TOF MS.

Cox CR, Saichek NR, Schweizer HP, Voorhees KJ.

Bacteriophage. 2014 Apr 25;4:e29011. eCollection 2014.

Supplemental Content

Support Center